Palvella Reports Q3 2026 Financial Results and FDA Priority Review for QTORIN
Palvella (PVLA) reported its third-quarter 2026 financial results, highlighted by a significant regulatory milestone: the FDA has accepted the New Drug Application for QTORIN rapamycin to treat microcystic lymphatic malformations. The FDA granted priority review with a target action date set for February 28, 2027. Management anticipates peak annual U.S. sales for this candidate could exceed $1 billion, supported by an estimated patient population of over 30,000 and projected annual therapy costs between $100,000 and $200,000. Financially, the company reported a net loss of $24.6 million ($1.70 per share) for the quarter, an increase from $11.3 million in the prior year, driven by rising R&D and G&A expenses. Despite the widening loss, Palvella maintains a strong liquidity position with $236.7 million in cash and equivalents. Looking ahead, the company plans to initiate Phase 3 studies for cutaneous venous malformations and Phase 2 trials for QTORIN-pitavastatin in the fourth quarter of 2026.